Literature DB >> 19593174

Targeted naltrexone for problem drinkers.

Henry R Kranzler1, Howard Tennen, Stephen Armeli, Grace Chan, Jonathan Covault, Albert Arias, Cheryl Oncken.   

Abstract

This study aimed to replicate and extend prior research showing that the targeted use of naltrexone is a useful strategy to reduce heavy drinking. We compared the effects of naltrexone with those of placebo in a sample of 163 individuals (58.3% male) whose goal was to reduce their drinking to safe limits. Patients received study medication (ie, naltrexone 50 mg or placebo) and were instructed to use it daily or targeted to situations identified by them as being high risk for heavy drinking. An interactive voice response system was used to obtain daily reports of drinking and medication use during the 12-week trial. Analyses were conducted using hierarchical linear modeling, with sex as a potential moderator variable. On the primary outcome measure, mean drinks per day, at week 12, men in the targeted naltrexone group drank significantly less than patients in the other groups did. On a secondary outcome measure, drinks per drinking day, during week 12, the targeted naltrexone group drank significantly less than the other groups did, with no moderating effect of sex. These results support the use of a targeted approach to reduce drinking among heavy drinkers, particularly men, but argue for the use of additional strategies or more efficacious medications than naltrexone to increase the effects of such an intervention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19593174      PMCID: PMC3184851          DOI: 10.1097/JCP.0b013e3181ac5213

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  19 in total

1.  Measurement and prediction of medication compliance in problem drinkers.

Authors:  Richard Feinn; Howard Tennen; Joyce Cramer; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2003-08       Impact factor: 3.455

2.  Using daily interactive voice response technology to measure drinking and related behaviors in a pharmacotherapy study.

Authors:  Henry R Kranzler; Khamis Abu-Hasaballah; Howard Tennen; Richard Feinn; Kevin Young
Journal:  Alcohol Clin Exp Res       Date:  2004-07       Impact factor: 3.455

3.  A randomized clinical trial of brief interventions in primary care: summary of a WHO project.

Authors:  T F Babor; M Grant; W Acuda; F H Burns; C Campillo; F K Del Boca; R Hodgson; N N Ivanets; M Lukomskya; M Machona
Journal:  Addiction       Date:  1994-06       Impact factor: 6.526

4.  Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial.

Authors:  P Heinälä; H Alho; K Kiianmaa; J Lönnqvist; K Kuoppasalmi; J D Sinclair
Journal:  J Clin Psychopharmacol       Date:  2001-06       Impact factor: 3.153

5.  Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.

Authors:  Sakari Karhuvaara; Kaarlo Simojoki; Antti Virta; Markus Rosberg; Eliisa Löyttyniemi; Tommi Nurminen; Antero Kallio; Rauno Mäkelä
Journal:  Alcohol Clin Exp Res       Date:  2007-04-19       Impact factor: 3.455

Review 6.  Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.

Authors:  Carmen Bouza; Magro Angeles; Angeles Magro; Ana Muñoz; José María Amate
Journal:  Addiction       Date:  2004-07       Impact factor: 6.526

7.  Empirically based guidelines for moderate drinking: 1-year results from three studies with problem drinkers.

Authors:  M Sanchez-Craig; D A Wilkinson; R Davila
Journal:  Am J Public Health       Date:  1995-06       Impact factor: 9.308

8.  Naltrexone in the treatment of alcohol dependence.

Authors:  J R Volpicelli; A I Alterman; M Hayashida; C P O'Brien
Journal:  Arch Gen Psychiatry       Date:  1992-11

9.  Targeted naltrexone for early problem drinkers.

Authors:  Henry R Kranzler; Stephen Armeli; Howard Tennen; Ola Blomqvist; Cheryl Oncken; Nancy Petry; Richard Feinn
Journal:  J Clin Psychopharmacol       Date:  2003-06       Impact factor: 3.153

10.  Naltrexone and coping skills therapy for alcohol dependence. A controlled study.

Authors:  S S O'Malley; A J Jaffe; G Chang; R S Schottenfeld; R E Meyer; B Rounsaville
Journal:  Arch Gen Psychiatry       Date:  1992-11
View more
  29 in total

1.  A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men.

Authors:  Jon Morgenstern; Alexis N Kuerbis; Andrew C Chen; Christopher W Kahler; Donald A Bux; Henry R Kranzler
Journal:  J Consult Clin Psychol       Date:  2012-05-21

Review 2.  Targeted opioid receptor antagonists in the treatment of alcohol use disorders.

Authors:  Mark J Niciu; Albert J Arias
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

Review 3.  The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review.

Authors:  Lara A Ray; Christina S Barr; Julie A Blendy; David Oslin; David Goldman; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2011-09-06       Impact factor: 3.455

Review 4.  Pharmacotherapy of alcohol use disorders: seventy-five years of progress.

Authors:  Leah R Zindel; Henry R Kranzler
Journal:  J Stud Alcohol Drugs Suppl       Date:  2014

5.  Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms.

Authors:  Angela N Henderson-Redmond; Tammy E Lowe; Xi B Tian; Daniel J Morgan
Journal:  Brain Res Bull       Date:  2017-08-02       Impact factor: 4.077

Review 6.  Naltrexone: A Pan-Addiction Treatment?

Authors:  Elias Aboujaoude; Wael O Salame
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

Review 7.  Sex and gender differences in substance use disorders.

Authors:  R Kathryn McHugh; Victoria R Votaw; Dawn E Sugarman; Shelly F Greenfield
Journal:  Clin Psychol Rev       Date:  2017-11-10

8.  Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.

Authors:  Henry R Kranzler; Jonathan Covault; Richard Feinn; Stephen Armeli; Howard Tennen; Albert J Arias; Joel Gelernter; Timothy Pond; Cheryl Oncken; Kyle M Kampman
Journal:  Am J Psychiatry       Date:  2014-04       Impact factor: 18.112

9.  Daily relations among affect, urge, targeted naltrexone, and alcohol use in young adults.

Authors:  Krysten W Bold; Lisa M Fucito; William R Corbin; Kelly S DeMartini; Robert F Leeman; Henry R Kranzler; Stephanie S O'Malley
Journal:  Exp Clin Psychopharmacol       Date:  2016-10       Impact factor: 3.157

Review 10.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Authors:  Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney
Journal:  Addiction       Date:  2012-10-17       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.